Atrasentan in Patients with IgA Nephropathy

H Hiddo J.L. Heerspink (George Institute for Global Health, University of New South Wales, Sydney) M Meg Jardine (National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney) D Donald E. Kohan (Division of Nephrology, University of Utah Health, Salt Lake City) R Richard A. Lafayette (Stanford University, Stanford, CA) A Adeera Levin A Adrian Liew (Mount Elizabeth Novena Hospital, Singapore) H Hong Zhang A Amit Lodha (Novartis, East Hanover, NJ) T Todd Gray (Chinook Therapeutics, Seattle) Y Yi Wang R Ronny Renfurm (Novartis Pharma, Basel, Switzerland) J Jonathan Barratt

Article Details

Volume / Issue Vol. 392, Issue 6
Published February 06, 2025
Pages 544-554
ISSN 0028-4793
Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society

ISSN: 0028-4793 Social Sciences

Authors (12)

H

Hiddo J.L. Heerspink

George Institute for Global Health, University of New South Wales, Sydney

M

Meg Jardine

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney

D

Donald E. Kohan

Division of Nephrology, University of Utah Health, Salt Lake City

R

Richard A. Lafayette

Stanford University, Stanford, CA

A

Adeera Levin

A

Adrian Liew

Mount Elizabeth Novena Hospital, Singapore

H

Hong Zhang

A

Amit Lodha

Novartis, East Hanover, NJ

T

Todd Gray

Chinook Therapeutics, Seattle

Y

Yi Wang

R

Ronny Renfurm

Novartis Pharma, Basel, Switzerland

J

Jonathan Barratt